Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan liposomal + sintilimab + lenvatinib
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Xi'an Jiaotong University
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
irinotecan liposomal + sintilimab + lenvatinib is a combination therapy being evaluated for the second-line treatment of advanced gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma. This regimen combines three distinct therapeutic modalities: a liposomal formulation of the cytotoxic topoisomerase I inhibitor irinotecan, the PD-1-targeting monoclonal antibody sintilimab, and the multi-kinase inhibitor lenvatinib. Irinotecan liposomal provides sustained drug exposure and improved tumor penetration compared to conventional irinotecan. Sintilimab acts as an immune checkpoint inhibitor, restoring T-cell activity against tumor cells. Lenvatinib targets multiple receptor tyrosine kinases involved in angiogenesis and tumor growth, including VEGFR and FGFR, and has been shown to modulate the tumor microenvironment to enhance the efficacy of immunotherapy. This triplet combination is currently being studied in a Phase 4 clinical trial sponsored by the First Affiliated Hospital of Xi'an Jiaotong University.
- Other names
- Irinotecan liposomes combined with sintilimab and lenvatinibIrinotecan Hydrochloride Liposome Injection + Sintilimab + Lenvatinib
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on irinotecan liposomal + sintilimab + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan liposomal + sintilimab + lenvatinib.